The most common semaglutide side effects are gastrointestinal
Across every semaglutide product, the most common adverse reactions are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. In the Wegovy 2.4 mg trials, 73% of people reported at least one GI reaction versus 47% on placebo; most were mild or moderate and short-lived (Wegovy FDA label, 2025).
How often they appear depends heavily on the dose and the population studied. Ozempic and Rybelsus were tested in adults with type 2 diabetes at lower semaglutide doses, while Wegovy 2.4 mg was tested in adults with obesity at a higher dose — the main reason Wegovy's rates run higher. Lower-frequency GI effects on the labels include dyspepsia (indigestion), acid reflux (GERD), belching, flatulence, gastritis, and abdominal distension.
Every label agrees these reactions are 'most frequently reported during dosage escalation' — they tend to spike when the dose goes up and ease as the body adjusts.
How side effects change over titration
Semaglutide is deliberately started at a low, non-therapeutic dose and stepped up slowly to blunt GI side effects. This is why side effects tend to be worst in the first weeks after each increase and then settle. The Wegovy 2.4 mg label reports median durations of roughly 8 days for nausea, 2 days for vomiting, and 3 days for diarrhea, whereas constipation lasted a median of about 47 days.
The following FDA-label titration schedules are provided as reference only — this is what the labels print, not a recommendation for any individual. A prescriber sets and adjusts your actual dose based on your response and tolerability, and may hold or slow the schedule. Do not self-titrate, skip, double, or speed up doses:
Higher doses trade more effect for more GI side effects. In the STEP UP trial behind Wegovy's high-dose 7.2 mg (Wegovy HD, FDA-approved March 2026), 18.5% of people needed a dose reduction for adverse events versus 12.4% on 2.4 mg, though discontinuation stayed low (5.4% vs 4%).
- Ozempic (type 2 diabetes): 0.25 mg once weekly for 4 weeks → 0.5 mg → 1 mg → up to 2 mg, each step after at least 4 weeks, only if the prescriber decides more glycemic control is needed (Ozempic FDA label, 2025).
- Wegovy (weight management): 0.25 mg once weekly → 0.5 → 1 → 1.7 → 2.4 mg, escalating monthly, with a higher 7.2 mg option (Wegovy HD) for selected adults (Wegovy FDA label, 2025).
- Rybelsus (oral, type 2 diabetes): 3 mg once daily for 30 days (this dose isn't effective for glucose control) → 7 mg → 14 mg, each step after at least 30 days if needed (Rybelsus FDA label, 2024).
- Rybelsus must be taken on an empty stomach with ≤4 oz of plain water, at least 30 minutes before the first food, drink, or other medication — otherwise absorption drops.
Serious and rare risks: pancreatitis, gallbladder, kidney, and ileus
Several serious reactions appear in the Warnings and Precautions sections of the semaglutide labels. They are uncommon, but they carry more weight than the everyday GI effects.
Acute pancreatitis has been reported with GLP-1 receptor agonists including semaglutide; labels instruct clinicians to stop the drug promptly if pancreatitis is suspected. Warning signs are severe, persistent abdominal pain that may radiate to the back, sometimes with vomiting.
Acute gallbladder disease (gallstones, cholecystitis) is more frequent on semaglutide: in the Wegovy adult trials, cholelithiasis occurred in 1.6% on Wegovy versus 0.7% on placebo, and cholecystitis in 0.6% versus 0.2%. Rapid weight loss itself raises gallstone risk.
Acute kidney injury can result from dehydration caused by nausea, vomiting, and diarrhea — there have been postmarketing reports of worsening kidney function, sometimes requiring dialysis. Bowel obstruction / ileus is listed as a postmarketing reaction (the EU label classifies intestinal obstruction as 'rare'); warning signs include severe bloating, abdominal pain, and inability to pass stool or gas. Semaglutide also delays gastric emptying, which has led to a label warning about pulmonary aspiration during general anesthesia or deep sedation — tell any surgeon or anesthesiologist you take it.
The thyroid C-cell boxed warning and contraindications
All semaglutide products carry the FDA's most prominent alert, a boxed warning: in rodents, semaglutide caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether it does so in humans is unknown, because the human relevance of the rodent finding hasn't been determined.
Because of this, semaglutide is contraindicated in anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Labels advise counseling patients on symptoms of thyroid tumors such as a neck mass, difficulty swallowing, shortness of breath, or persistent hoarseness.
Semaglutide is also contraindicated in people who have had a serious hypersensitivity reaction to it. Serious allergic reactions, including anaphylaxis and angioedema, have been reported; the drug should be stopped and medical help sought if one occurs.
The NAION vision signal and diabetic retinopathy
A newer safety topic is NAION — non-arteritic anterior ischemic optic neuropathy — a form of sudden, usually painless vision loss in one eye. In June 2025, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded NAION is a 'very rare' side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy), affecting up to about 1 in 10,000 people, and recommended it be added to product information; treatment should be stopped if NAION occurs. A 2026 consensus statement from NANOS and the American Academy of Ophthalmology reviewed the evidence linking GLP-1 drugs, particularly semaglutide, to NAION.
Separately, in people with type 2 diabetes, the labels flag diabetic retinopathy complications, first seen in a semaglutide cardiovascular outcomes trial; those with a history of diabetic retinopathy should be monitored. Any sudden change in vision warrants urgent evaluation.
These are examples of why moving safety data matters: labels are updated as evidence accumulates, so a prescriber and the current FDA label are the authoritative source for your situation.
Red-flag symptoms: when to seek care
Most semaglutide side effects are manageable, but some symptoms signal a possible serious reaction and should prompt medical attention. This list is educational; if you think you're having an emergency, call your local emergency number.
Because dehydration from GI side effects can spiral into kidney problems, staying hydrated and reporting persistent vomiting or diarrhea to a clinician matters. None of this replaces personalized medical advice — your prescriber and pharmacist know your full history.
- Severe, persistent stomach pain, especially if it radiates to your back or comes with vomiting — a possible sign of pancreatitis.
- Pain in the upper right belly, fever, yellowing of the skin or eyes, or clay-colored stools — possible gallbladder disease.
- Severe bloating with an inability to pass stool or gas — a possible sign of bowel obstruction/ileus.
- Sudden vision loss or changes in one or both eyes — evaluate urgently (possible NAION).
- Signs of a serious allergic reaction: swelling of the face, lips, tongue or throat, trouble breathing, or a widespread rash.
- A lump or swelling in the neck, trouble swallowing, or persistent hoarseness — report to your clinician (thyroid warning).
Compounded semaglutide: a different safety picture
Compounded semaglutide — often sold through telehealth during periods of brand shortage — is not an FDA-approved finished drug. That means the frequency data on this page, which come from the FDA-reviewed brand labels, do not automatically apply to compounded products, and their safety and side-effect profiles have not been established by the FDA.
Compounded versions can differ in ingredients (for example, semaglutide salts), concentration, and dosing instructions, and dosing errors have been a documented concern with self-administered compounded GLP-1s. If you're considering or using a compounded product, discuss it with a licensed prescriber and treat any dosing instructions as clinician-directed, not self-managed.
As an affiliate comparison site, we don't sell or prescribe medication; we compare licensed telehealth providers and link you to them. Use our tools to understand your options, then let a qualified clinician make the medical decisions.